NBEA

Across TCGA pan-cancer cohorts, NBEA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NBEA data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher NBEA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NBEA expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, PDAC, and HNSC are the cancer types where NBEA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.842	0.658	.004	9	view →
PDAC	DFS	Median	All	0.684	0.834	.018	6	view →
HNSC	DFS	Tertile	II,III,IV	0.904	0.989	.035	2	view →
LUAD	OS	Quartile	II,III,IV	0.799	0.288	.017	2	view →
LSCC	DFS	Tertile	II,III,IV	0.806	1.000	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NBEA–GBM (DFS)

Open the GBM breakdown →